Howard A. Fine, MD, has been appointed to lead the newly established neuro-oncology program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, effective February 2. He will serve as Director of the Brain Tumor Center and Associate Director for Translational Research in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, as well as Chief of the Division of Neuro-Oncology in the Department of Neurology at NewYork-Presbyterian/Weill Cornell. He has also been named to the faculty of the Departments of Medicine and Neurosurgery at Weill Cornell Medical College.
At NewYork-Presbyterian/Weill Cornell, Dr. Fine will establish a state-of-the-art research and clinical program that will provide cutting-edge treatments for patients with brain tumors. Prior to joining NewYork-Presbyterian/Weill Cornell, he built two of the nation’s leading neuro-oncology programs—the Dana-Farber Cancer Institute Center for Neuro-Oncology at Harvard Medical School and the Neuro-Oncology Branch at the National Institutes of Health. He has run a basic and translational science laboratory throughout his 26-year career and has been involved in more than 100 brain tumor clinical trials.
“The recruitment of Dr. Howard Fine will be transformational for the Department of Neurology and the clinical neuroscience programs at NewYork-Presbyterian Hospital and Weill Cornell Medical College,” said Matthew E. Fink, MD, Neurologist-in-Chief at NewYork-Presbyterian/Weill Cornell and the Louis and Gertrude Feil Professor and Chairman of the Department of Neurology at Weill Cornell Medical College. “He brings knowledge and expertise to a specialized area that we have not pursued in the past, and he will help this key program fulfill its mission and vision.”
Dr. Fine received his medical degree at the Mount Sinai School of Medicine. He completed an internship and residency in internal medicine at the Perelman School of Medicine at the University of Pennsylvania, followed by a fellowship in medical oncology at the Dana-Farber Cancer Institute and Harvard Medical School. Most recently, Dr. Fine served as Deputy Director of the Cancer Center and Director of the Brain Tumor Center at NYU Langone.
“As part of the Meyer Cancer Center, the Weill Cornell Brain Tumor Center at NewYork-Presbyterian Hospital will offer its patients the highest level of comprehensive state-of-the-art care, delivered by nationally renowned clinical experts from multiple disciplines,” Dr. Fine said.
View the full press release from Weill Cornell Medical College at weill.cornell.edu. ■
